Overview

Coronary artery disease (CAD) is the leading cause of morbidity and mortality in developed countries. In addition, many patients suffer from valvular and aortic disease. Although various tools are available to identify patients with cardiovascular (CV) disease at risk for major adverse cardiac events (MACE), the identification of these patients remains a clinical challenge.

One promising avenue is the use of different serum biomarkers involved in atherothrombosis which could provide an easy and cost-effective step in risk stratification.

Eligibility

Inclusion Criteria:

• Patients referred from the Cardiology clinic for routine CCTA.

Exclusion Criteria:

• Pregnancy
• Severe renal insufficiency
• Severe allergy to contrast medium
• Inability to obtain informed consent
• Age below 18 years